Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis

  title={Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis},
  author={A. Manouchehrinia and C. Constantinescu},
  journal={Current Neurology and Neuroscience Reports},
  • A. Manouchehrinia, C. Constantinescu
  • Published 2012
  • Medicine
  • Current Neurology and Neuroscience Reports
  • Multiple sclerosis (MS) is a leading cause of disability among young adults and has a significant economic impact on society. Although MS is not currently a curable disease, costly treatments known as disease-modifying therapies (DMTs) are available to reduce the disease impact in certain types of MS. In the current economic downturn, cost-effectiveness analysis (CEA) of therapies in MS has become an important part of the decision-making process in order to use resources efficiently in the face… CONTINUE READING
    18 Citations

    Tables and Topics from this paper

    Paper Mentions

    Interventional Clinical Trial
    Purpose of study is to determine safety and efficacy of use of autologous Adipose-Derived cellular Stromal Vascular Fraction (AD-cSVF) suspended in Normal Saline and delivered via… Expand
    ConditionsAutoimmune, Multiple Sclerosis
    InterventionDevice, Procedure
    Multiple sclerosis: basic knowledge and new insights in perioperative management
    • 39


    Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis.
    • 44